No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ADCT ADC Therapeutics
- 4.340
- -0.100-2.25%
Close Apr 26 16:00 ET
- 4.460
- +0.120+2.76%
Post 17:40 ET
359.41MMarket Cap-1476P/E (TTM)
4.510High4.210Low323.50KVolume4.440Open4.440Pre Close1.41MTurnover0.51%Turnover RatioLossP/E (Static)82.81MShares6.04052wk High-2.42P/B274.41MFloat Cap0.36052wk Low--Dividend TTM63.23MShs Float56.590Historical High--Div YieldTTM6.76%Amplitude0.360Historical Low4.352Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Amgen's Blincyto Data Send Cullinan Higher
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics with a Buy and maintains $9 price target.
Buy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial Progress
Analysts Conflicted on These Healthcare Names: ADC Therapeutics (ADCT), Adial Pharmaceuticals (ADIL) and Steris (STE)
ADC Therapeutics Showcases Cancer Treatment Innovations
Guggenheim Reiterates Buy on ADC Therapeutics
Guggenheim analyst Michael Schmidt reiterates ADC Therapeutics with a Buy.
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg